



US005306731A

# United States Patent [19]

[11] Patent Number: **5,306,731**

**Epstein**

[45] Date of Patent: **Apr. 26, 1994**

[54] **METHOD AND PRODUCTS FOR TREATING THE EYE**

[75] Inventor: **David L. Epstein**, Wayland, Mass.

[73] Assignee: **Massachusetts Eye and Ear Infirmary**, Boston, Mass.

[21] Appl. No.: **669,381**

[22] Filed: **Mar. 14, 1991**

### Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 514,488, Apr. 26, 1990, which is a continuation-in-part of Ser. No. 123,797, Nov. 23, 1987, which is a continuation-in-part of Ser. No. 745,325, Jun. 14, 1985, abandoned.

[51] Int. Cl.<sup>5</sup> ..... **A61K 31/195**; A61K 31/19

[52] U.S. Cl. .... **514/562**; 514/571;  
514/913

[58] Field of Search ..... 514/571, 562, 913

### [56] References Cited

#### U.S. PATENT DOCUMENTS

4,590,210	5/1986	Landham .....	514/548
4,596,771	6/1986	Cidlowski et al. ....	435/7
4,777,130	10/1988	Maes .....	435/7
4,826,879	5/1989	Yamamoto et al. ....	514/657
4,829,011	5/1989	Gibbons .....	436/512
4,847,209	7/1989	Lewis et al. ....	436/533
4,891,324	1/1990	Pease et al. ....	436/519
4,965,192	10/1990	Maes .....	435/7

#### FOREIGN PATENT DOCUMENTS

883792	10/1971	Canada .
WO86/07259	12/1986	PCT Int'l Appl. .
1141422	1/1969	United Kingdom .

#### OTHER PUBLICATIONS

Epstein et al., "Influences of glutathione and sulfhydryl containing compounds on aqueous humor outflow function," Chem. Abst. vol. 113:523 (Aug. 27, 1990).

Epstein et al., "N-ethylmaleimide increases the facility of aqueous outflow of excised monkey & calf eyes", Invest. Ophthalmol. Vis. Sci. 22:752-756 (1982).

Magro et al., "Effect of sulfhydryl-reactive ATPase inhibitors upon mast cell and basophil activation", Int.

Archives of Allergy and Applied Immunology 77:41-45 (1983).

Epstein et al., "The effect of diamide on lens glutathione and lens membrane function", Invest. Ophthalmol. Vis. Sci. 9:629-638 (1970).

Lindenmayer et al., "Morphology and Function of the Aqueous Outflow System in Monkey Eyes Perfused with Sulfhydryl Reagents", Invest. Ophthalmol. Vis. Sci. 24:710-717 (1983).

Epstein et al., "Effect of iodacetamide perfusion on outflow facility and metabolism of the trabecular meshwork", Invest. Ophthalmol. Vis. Sci. 20:625-631 (May 1981).

Anderson et al., "Metabolism of calf trabecular (reticular) meshwork", Invest. Ophthalmol. Vis. Sci. 19:13-20 (Jan. 1980).

Kahn et al., "Glutathione in Calf Trabecular Meshwork and its Relation to Aqueous Humor Outflow Facility", Invest. Ophthalmol. Vis. Sci. 24:1283-1287 (1983).

Scott et al., "Glutathione Peroxidase of Calf Trabecular Meshwork", Invest. Ophthalmol. Vis. Sci. 25:599-602 (1984).

Freddo et al., "Influence of Mercurial Sulfhydryl Agents on Aqueous Outflow Pathways in Enucleated Eyes", Invest. Ophthalmol. Vis. Sci. 25:278-285 (1984).  
Epstein et al., "The Biochemistry of Outflow Mechanisms", Applied Pharmacology in the Medical Treatment of Glaucomas pp. 135-150 (Aug. 1984).

(List continued on next page.)

Primary Examiner—Zohreh Fay

Attorney, Agent, or Firm—Wolf, Greenfield & Sacks

### [57] ABSTRACT

This invention is directed to improved treatment for glaucoma. It involves delivering to the eye molecules which increase the outflow of aqueous humor, in conjunction with masking agents. The masking agents reduce the side effects of the therapeutically active molecules by masking the sulfhydryl reactive groups on the molecules. The masking agents can be delivered separately from the molecules, or as adducts of the molecules.

**27 Claims, No Drawings**